Secondary Private Group
|
|
26
|
23385
|
31 January 2024
|
Eribulin
|
|
3
|
944
|
12 April 2024
|
Atrophy
|
|
11
|
449
|
31 March 2024
|
Exemestane (aromasin) and Everolimus (Afinitor)
|
|
15
|
913
|
20 March 2024
|
Is Enhertu available in the UK, on the NHS
|
|
20
|
823
|
18 March 2024
|
Have you recieved elacestrant (orserdu)?
|
|
0
|
115
|
18 March 2024
|
Xgeva (denosumab) and low White blood count
|
|
1
|
162
|
16 March 2024
|
Change of treatment - PICC or central line
|
|
12
|
267
|
16 March 2024
|
Capecitabine older people
|
|
7
|
231
|
16 March 2024
|
CA15-3 marker
|
|
7
|
504
|
16 March 2024
|
BCN Response Time
|
|
3
|
243
|
14 March 2024
|
Weight gain in short space of time ?
|
|
5
|
581
|
13 March 2024
|
Tamoxifen Brand Change
|
|
3
|
156
|
10 March 2024
|
Post surgery anxiety
|
|
6
|
310
|
18 February 2024
|
Terrible balance problem
|
|
7
|
341
|
8 February 2024
|
Cancer Research Awareness
|
|
0
|
138
|
4 February 2024
|
Xeloda and bone recurrence
|
|
3
|
307
|
31 January 2024
|
Atezolizumab and Nab-paclitaxel (Abraxane) experience
|
|
5
|
891
|
30 January 2024
|
About to start Trodelvy, any information please
|
|
6
|
3316
|
28 January 2024
|
Xeloda delay
|
|
13
|
457
|
21 January 2024
|
Enhertu
|
|
20
|
15160
|
14 January 2024
|
The dreaded canula
|
|
12
|
478
|
11 January 2024
|
Sacituzumab govitecan (Trodelvy)
|
|
3
|
386
|
11 January 2024
|
HER2-low trastuzumab deruxtecan (Enhertu)
|
|
1
|
1202
|
1 January 2024
|
Covid 19
|
|
7
|
469
|
31 December 2023
|
Ribociclib dose reduced
|
|
7
|
396
|
29 December 2023
|
Succesful on Capecitabine
|
|
23
|
1345
|
24 December 2023
|
Xeloda dosage
|
|
5
|
308
|
19 December 2023
|
Letrozole advantages
|
|
12
|
800
|
17 December 2023
|
Long story and MRI advice
|
|
5
|
708
|
4 December 2023
|